First diabetes pill to protect kidneys
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with type 2 diabetes
- You’re at least 18 years old
- Your weight/height is above a basic healthy threshold (BMI over 18.5)
- You are either not taking diabetes drugs yet, or only taking metformin, and you can switch by chance to dapagliflozin or metformin
- Your kidney blood test is at least moderately okay (eGFR 45 or higher)
- You agree to take part by signing the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.